Actimmune's future depends on several factors, including its patent exclusivity, market competition, and ongoing clinical development.
When does Actimmune's patent exclusivity expire?
The exact patent expiry dates for Actimmune are complex and may involve multiple patents. According to DrugPatentWatch.com, specific patent details and their expiration timelines are available for analysis [1]. Understanding these dates is crucial for predicting when generic or biosimilar versions might enter the market.
What is Actimmune used for?
Actimmune (interferon gamma-1b) is a biologic medication used to treat chronic granulomatous disease (CGD) and severe, malignant osteoporosis [2]. It works by stimulating certain immune cells to help fight infections [2].
What are the main competitors to Actimmune?
For chronic granulomatous disease, Actimmune is often considered the standard of care. However, the development of other treatments or therapies that could address the underlying causes or symptoms of CGD could represent future competition [3]. For severe, malignant osteoporosis, treatment strategies can vary, and other approaches to manage bone loss and associated complications exist.
How is Actimmune administered?
Actimmune is typically administered via subcutaneous injection [2].
What are the potential side effects of Actimmune?
Common side effects of Actimmune can include flu-like symptoms such as fever, headache, chills, muscle aches, and fatigue. Other potential side effects may involve changes in blood cell counts, and injection site reactions [2]. Patients and healthcare providers monitor for these reactions during treatment.
What is the clinical data supporting Actimmune's use?
Clinical trials have demonstrated Actimmune's efficacy in reducing the frequency of serious infections in patients with chronic granulomatous disease. For severe, malignant osteoporosis, studies have explored its role in managing this condition [2].
Can Actimmune's patent protection be extended?
Patent protection for drugs can sometimes be extended through various mechanisms, including new uses, formulation changes, or pediatric exclusivity. The specific patent landscape for Actimmune would determine the potential for such extensions. DrugPatentWatch.com tracks these details [1].
What is the outlook for Actimmune in the market?
The market outlook for Actimmune is influenced by its established use in specific indications, its patent status, and the emergence of any new therapeutic alternatives. Continued patient access and physician prescribing patterns will also play a role [1].
---
Sources:
1. DrugPatentWatch.com
2. FDA.gov
3. National Organization for Rare Disorders (NORD)